BCDA - BioCardia GAAP EPS of -$0.67 misses by $0.02 revenue of $1.4M beats by $1.35M
2023-03-29 16:03:39 ET
- BioCardia press release ( NASDAQ: BCDA ): FY GAAP EPS of -$0.67 misses by $0.02 .
- Revenue of $1.4M (+40.0% Y/Y) beats by $1.35M .
- Research and development increased to $8.8 million in 2022, compared to $8.6 million in 2021, primarily due to increased expenses in support of the CardiAMP Heart Failure Trial.
- Selling, general and administrative expenses decreased to $4.4 million in 2022, compared to $5.1 million in 2021, primarily due to lower professional fees, stock-based compensation expense and rent expense.
- Our net loss was $11.9 million in 2022, compared to $12.6 million in 2021.
- Net cash used in operations was approximately $10.6 million in 2022, compared to $10.4 million in 2021. The Company ended the year with cash and cash equivalents totaling $7.4 million, providing runway into the third quarter of 2023.
For further details see:
BioCardia GAAP EPS of -$0.67 misses by $0.02, revenue of $1.4M beats by $1.35M